Pharmaceutical - Johnson & Johnson, Rare diseases

Filter

Popular Filters

FDA backs Janssen’s Sylvant for rare disease

24-04-2014

The US Food and Drug Administration yesterday approved Johnson & Johnson subsidiary Janssen Biotech’s…

Janssen BiotechJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRare diseasesRegulationsiltuximabSylvantUSA

Janssen files for simultaneous US and EU approval for Castleman disease drug

04-09-2013

Janssen Research & Development, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), yesterday…

EuropeJanssenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRare diseasesRegulationsiltuximab

Scottish regulator backs restricted NHS use of Janssen's Zytiga; negative on BioMarin's Firdapse

13-08-2012

The Scottish Medicines Consortium (SMC) announced yesterday that it has accepted Johnson & Johnson (NYSE:…

BioMarin PharmaceuticalEuropeFirdapseJanssenJohnson & JohnsonOncologyPharmaceuticalPricingRare diseasesRegulationZytiga

CHMP positive on first gene therapy, Glybera; and more opinions

23-07-2012

Reversing an earlier negative opinion (The Pharma Letter April 22), the European Medicines Agency's Committee…

AdcetrisBiotechnologyCelgeneDacogenEuropeGlyberaIstodaxJanssen-CilagJohnson & JohnsonOncologyPfizerPharmaceuticalRare diseasesRegulationTakeda PharmaceuticalsuniQureXalkori

FDA approves Alexion’s Soliris for rare pediatric blood disorder and J&J’s Remicade for children with UC

25-09-2011

The US Food and Drug Administration on Friday approved Alexion Pharmaceuticals’ (Nasdaq: ALXN) Soliris…

Alexion PharmaceuticalsAnti-Arthritics/RheumaticsJohnson & JohnsonNorth AmericaPharmaceuticalRare diseasesRegulationRemicadeSolaris

Back to top